medRxiv 预印本Codex · 实盘不做把握 3/10
北京时间·🕒 发布 07-22(UTC日)仅日期·时区推断·⟳ 抓取 16:09:23回填·⚡ 决策 07-27 16:20:55·92.5 天前
medRxiv预印本披露阿伐可泮上市后肝毒性和日本VBDS致死病例
该预印本来自Amgen全球安全数据库，方向上对Tavneos/avacopan为新增安全压力，但结论同时称多数肝脏事件为停药后可逆实验室异常，且未出现新的安全风险。
📄 原文medRxiv 预印本↗ 原文
A Post-Marketing Evaluation of Avacopan Safety with a Focus on Hepatic Adverse Events
BackgroundAvacopan, an oral complement C5a receptor inhibitor, has been shown to help patients with anti-neutrophil cyt…
不做 Amgen（AMGN.US）
方向偏负面但只是5天前预印本安全性汇总，未见监管升级、销售指引下修或相对Amgen市值足够大的损害；股价事件后未负向重定价，做空催化强度和量级均不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
消息传播链
- medRxiv发布Amgen全球安全数据库回顾性描述分析，披露截至2026-01-20的avacopan肝脏不良事件和31例VBDS病例。市场反应:AMGN.US在2026-07-22收跌0.05%，随后两日上涨，未见该论文触发明显负面重定价。
- 2026-07-27市场反应price_snapshot非一手AMGN.US截至2026-07-24收盘价376.04美元，近5日+2.66%、近20日+6.58%，事件后走势不支持强公司级利空已被交易。市场反应:事件窗口内未见持续下跌。
关键理由
- 该预印本来自Amgen全球安全数据库，方向上对Tavneos/avacopan为新增安全压力，但结论同时称多数肝脏事件为停药后可逆实验室异常，且未出现新的安全风险。
- 阿伐可泮安全风险已属获批后标签和药物警戒框架内事项，本次是5天前预印本的描述性安全汇总，不是监管限制、撤药、黑框升级或销售指引下修。
- Amgen（AMGN.US）为超大市值药企，Tavneos单品相对公司收入和市值的量级不足以支持因一篇预印本建立可执行空头。
主要风险
- 若FDA/PMDA后续基于VBDS致死病例要求加强警示、限制适应症或暂停销售，才会升级为公司级风险事件。
- 目前无法从该信号量化Tavneos销售受损金额，且Amgen股价在事件后未出现同向负面重定价。
反向证据
- 做空前查反向 · 来源 kb_search · 日期 2026-07-27 · 影响 weakens
内部KB未命中同一安全事件的投研扩散或监管升级，未支持建立Amgen可执行空头。
检索:avacopan Tavneos hepatic adverse events VBDS Amgen safety Japan - 做空前查反向 · 来源 kb_search · 日期 2026-07-27 · 影响 weakens
内部KB未提供Tavneos销售额或本次事件导致销售受损的硬数字；量级无法支撑公司级短线风险。
检索:Amgen Tavneos avacopan revenue sales 2025 2026 product sales hepatic warning
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
原文全文
展开原文 · 2,012 字
A Post-Marketing Evaluation of Avacopan Safety with a Focus on Hepatic Adverse Events
BackgroundAvacopan, an oral complement C5a receptor inhibitor, has been shown to help patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) achieve and sustain remission with reduced glucocorticoid exposure and associated toxicity. As of January 20, 2026, estimated global post-marketing exposure exceeded 25,000 patient-years. Hepatic adverse events (AEs), predominantly liver enzyme elevations observed during clinical development, remain an important post approval safety risk. Since approval, vanishing bile duct syndrome (VBDS), a rare but serious complication of drug induced liver injury (DILI) has been reported with avacopan use. This analysis evaluated Amgens global safety database data to characterize hepatic adverse event reports associated with avacopan, including VBDS.
MethodsWe conducted a retrospective descriptive analysis of hepatic AEs recorded in the Amgen global safety database.
ResultsAs of 20 January 2026, serious hepatic AEs were reported at approximately 31 events/1,000 patient-years. The majority of hepatic events comprised laboratory abnormalities that resolved following avacopan discontinuation. Thirty-one VBDS cases were reported and, of those, 27 originated from Japan. Fatal VBDS cases were reported predominantly from Japan and occurred in patients >65 years.
ConclusionsHepatotoxicity remains an important avacopan-specific safety risk. Post-marketing data indicate that most hepatic events are reversible laboratory abnormalities; however, serious liver injury and VBDS, including fatal outcomes, have been reported, predominantly from Japan. No new safety risks have emerged from the ongoing Japanese post-marketing study. Further investigation is warranted to understand potential mechanisms underlying the disproportionate occurrence of serious VBDS events in Japanese patients and inform optimized risk-mitigation strategies.
主题词：rheumatology
BackgroundAvacopan, an oral complement C5a receptor inhibitor, has been shown to help patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) achieve and sustain remission with reduced glucocorticoid exposure and associated toxicity. As of January 20, 2026, estimated global post-marketing exposure exceeded 25,000 patient-years. Hepatic adverse events (AEs), predominantly liver enzyme elevations observed during clinical development, remain an important post approval safety risk. Since approval, vanishing bile duct syndrome (VBDS), a rare but serious complication of drug induced liver injury (DILI) has been reported with avacopan use. This analysis evaluated Amgens global safety database data to characterize hepatic adverse event reports associated with avacopan, including VBDS.
MethodsWe conducted a retrospective descriptive analysis of hepatic AEs recorded in the Amgen global safety database.
ResultsAs of 20 January 2026, serious hepatic AEs were reported at approximately 31 events/1,000 patient-years. The majority of hepatic events comprised laboratory abnormalities that resolved following avacopan discontinuation. Thirty-one VBDS cases were reported and, of those, 27 originated from Japan. Fatal VBDS cases were reported predominantly from Japan and occurred in patients >65 years.
ConclusionsHepatotoxicity remains an important avacopan-specific safety risk. Post-marketing data indicate that most hepatic events are reversible laboratory abnormalities; however, serious liver injury and VBDS, including fatal outcomes, have been reported, predominantly from Japan. No new safety risks have emerged from the ongoing Japanese post-marketing study. Further investigation is warranted to understand potential mechanisms underlying the disproportionate occurrence of serious VBDS events in Japanese patients and inform optimized risk-mitigation strategies.
主题词：rheumatology
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。